<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22952854</article-id>
      <article-id pub-id-type="pmc">3428299</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-12-08057</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0044010</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Computational Biology</subject>
            <subj-group>
              <subject>Genomics</subject>
              <subj-group>
                <subject>Genome Sequencing</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Heredity</subject>
              <subj-group>
                <subject>Linkage (Genetics)</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Genetics of Disease</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Immune Cells</subject>
              <subj-group>
                <subject>T Cells</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Immunity</subject>
              <subj-group>
                <subject>Immune Deficiency</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Genetics of the Immune System</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Model Organisms</subject>
            <subj-group>
              <subject>Yeast and Fungal Models</subject>
              <subj-group>
                <subject>Candida Albicans</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Dermatology</subject>
            <subj-group>
              <subject>Skin Infections</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Infectious Diseases</subject>
            <subj-group>
              <subject>Viral Diseases</subject>
              <subj-group>
                <subject>Human Papillomavirus Infection</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Inherited MST1 Deficiency Underlies Susceptibility to EV-HPV Infections</article-title>
        <alt-title alt-title-type="running-head">MST1 Deficiency in Patients with EV-HPV Infections</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Crequer</surname>
            <given-names>Amandine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Picard</surname>
            <given-names>Capucine</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patin</surname>
            <given-names>Etienne</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D&#x2019;Amico</surname>
            <given-names>Aurelia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abhyankar</surname>
            <given-names>Avinash</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Munzer</surname>
            <given-names>Martine</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Debr&#xE9;</surname>
            <given-names>Marianne</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Shen-Ying</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Saint-Basile</surname>
            <given-names>Genevi&#xE8;ve</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fischer</surname>
            <given-names>Alain</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Abel</surname>
            <given-names>Laurent</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Orth</surname>
            <given-names>G&#xE9;rard</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Casanova</surname>
            <given-names>Jean-Laurent</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Jouanguy</surname>
            <given-names>Emmanuelle</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, United States of America</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Paris Descartes University, Sorbonne Paris Cit&#xE9;, Necker Medicine Faculty, Paris, France</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U980, Paris, France</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Study Center for Primary Immunodeficiencies, Necker Hospital, AP-HP, Paris, France</addr-line>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <addr-line>Human Evolutionary Genetics, CNRS URA 3012 Genomes and Genetics Department, Pasteur Institute, Paris, France</addr-line>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <addr-line>Department of Pediatrics, American Memorial Hospital, Centre Hospitalier Regional et Universitaire (CHU) de Reims, Reims, France</addr-line>
      </aff>
      <aff id="aff7">
        <label>7</label>
        <addr-line>Pediatric Immuno-hematology Unit, Necker Hospital, AP-HP, Paris, France</addr-line>
      </aff>
      <aff id="aff8">
        <label>8</label>
        <addr-line>Laboratory of Normal and Pathological Development of the Immune System INSERM U768, Paris, France</addr-line>
      </aff>
      <aff id="aff9">
        <label>9</label>
        <addr-line>Department of Virology, Pasteur Institute, Paris, France</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Wurfel</surname>
            <given-names>Mark M.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>University of Washington, United States of America</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>Emmanuelle.jouanguy@inserm.fr</email></corresp>
        <fn fn-type="conflict">
          <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: AC CP EP LA GO JLC EJ. Performed the experiments: AC CP EP AD AA. Analyzed the data: AC CP EP AD AA MM MD SYZ GSB AF LA GO JLC EJ. Contributed reagents/materials/analysis tools: AC CP EP AD AA MM MD SYZ GSB AF LA GO JLC EJ. Wrote the paper: AC GO JLC EJ.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>8</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>8</issue>
      <elocation-id>e44010</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>3</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>7</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Crequer et al</copyright-holder>
        <license>
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Epidermodysplasia verruciformis (EV) is characterized by persistent cutaneous lesions caused by a specific group of related human papillomavirus genotypes (EV-HPVs) in otherwise healthy individuals. Autosomal recessive (AR) EVER1 and EVER2 deficiencies account for two thirds of known cases of EV. AR RHOH deficiency has recently been described in two siblings with EV-HPV infections as well as other infectious and tumoral manifestations. We report here the whole-exome based discovery of AR MST1 deficiency in a 19-year-old patient with a T-cell deficiency associated with EV-HPV, bacterial and fungal infections. MST1 deficiency has recently been described in seven patients from three unrelated kindreds with profound T-cell deficiency and various viral and bacterial infections. The patient was also homozygous for a rare <italic>ERCC3</italic> variation. Our findings broaden the clinical range of infections seen in MST1 deficiency and provide a new genetic etiology of susceptibility to EV-HPV infections. Together with the recent discovery of RHOH deficiency, they suggest that T cells are involved in the control of EV-HPVs, at least in some individuals.</p>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported by grants from INSERM, University Paris Descartes, the Rockefeller University, the Rockefeller University CTSA grant number 5UL1RR024143, and the St. Giles Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="7"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by persistent cutaneous lesions caused by a specific group of related human betapapillomavirus genotypes (EV-HPVs) in otherwise healthy individuals <xref ref-type="bibr" rid="pone.0044010-Orth1">[1]</xref>, <xref ref-type="bibr" rid="pone.0044010-Orth2">[2]</xref>. EV is also associated with a high risk of skin cancer. Many cases of EV are familial, and 10% of patients come from consanguineous families <xref ref-type="bibr" rid="pone.0044010-Orth2">[2]</xref>. This observation led Cockayne <italic>et al.</italic> to hypothesize in 1933 that EV resulted from autosomal recessive (AR) inborn errors of immunity against EV-HPVs <xref ref-type="bibr" rid="pone.0044010-Cockayne1">[3]</xref>. This hypothesis was confirmed by the discovery of the first two genetic etiologies of EV in 2002, mutations in <italic>EVER1</italic> and <italic>EVER2</italic>
<xref ref-type="bibr" rid="pone.0044010-Ramoz1">[4]</xref>, which added EV to the list of primary immunodeficiencies <xref ref-type="bibr" rid="pone.0044010-Casanova1">[5]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0044010-Alcais2">[8]</xref>. These genes, which are expressed in both keratinocytes and leukocytes, are involved in the control of intracellular zinc distribution <xref ref-type="bibr" rid="pone.0044010-Lazarczyk1">[9]</xref>. The inactivating mutations in <italic>EVER1</italic> or <italic>EVER2</italic> discovered to date account for approximately 75% of all cases reported worldwide <xref ref-type="bibr" rid="pone.0044010-Orth1">[1]</xref>, <xref ref-type="bibr" rid="pone.0044010-Orth2">[2]</xref>, <xref ref-type="bibr" rid="pone.0044010-Aochi1">[10]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0044010-Rady1">[16]</xref>. We recently identified two siblings with RHOH deficiency, EV-HPV infections, other cutaneous viral infections, a bronchopulmonary disease of unclear pathogenesis, and a Burkitt lymphoma <xref ref-type="bibr" rid="pone.0044010-Crequer1">[17]</xref>. These siblings do not display EV <italic>stricto sensu</italic>. Consistent with the patients&#x2019; broad phenotype, RHOH is found specifically in leukocytes, including T cells, but is absent from keratinocytes. RHOH-deficient patients have a T-cell defect characterized by abnormally low numbers of naive T cells, high numbers of memory T cells and impaired T-cell proliferation in response to TCR stimulation. The discovery of two RHOH-deficient patients suggests an important role for T cells in immunity to EV-HPVs, at least in some individuals. Of note, the T-cell defect in these two siblings also accounts for the development of infectious and tumoral signs other than EV-HPV infections <xref ref-type="bibr" rid="pone.0044010-Crequer1">[17]</xref>. In addition to inherited susceptibility to EV-HPV infections, an acquired form has been described in patients with HIV infection <xref ref-type="bibr" rid="pone.0044010-Rogers1">[18]</xref>, <xref ref-type="bibr" rid="pone.0044010-Daly1">[19]</xref>, renal allograft transplant recipients <xref ref-type="bibr" rid="pone.0044010-Rogers1">[18]</xref>, <xref ref-type="bibr" rid="pone.0044010-Lutzner1">[20]</xref> and in patients undergoing chemotherapy <xref ref-type="bibr" rid="pone.0044010-Rogers1">[18]</xref>, <xref ref-type="bibr" rid="pone.0044010-Gross1">[21]</xref> or hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficiency (SCID) caused by mutations in <italic>JAK3</italic> or <italic>IL2RG,</italic> which encodes the common gamma chain (&#x3B3;c) <xref ref-type="bibr" rid="pone.0044010-Rogers1">[18]</xref>, <xref ref-type="bibr" rid="pone.0044010-Laffort1">[22]</xref>. Intriguingly, EV-HPV lesions have not been reported after HSCT in patients with other inborn errors of immunity, suggesting that residual JAK3 and IL2RG deficiencies in keratinocytes may be involved in the pathogenesis of this condition <xref ref-type="bibr" rid="pone.0044010-Laffort1">[22]</xref>. Here, based on whole-exome sequencing (WES), which has successfully been used to identify novel immune deficiencies <xref ref-type="bibr" rid="pone.0044010-Byun1">[23]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0044010-Liu1">[25]</xref>, we describe the discovery of MST1 deficiency and a profound T-cell deficiency in a patient displaying EV-HPV infections as well as candidiasis and pulmonary infections.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Case Report</title>
        <p>The patient (P1) was born to first-cousin parents of Senegalese origin living in France (<xref ref-type="fig" rid="pone-0044010-g001">Figure 1A</xref>). He had a total of six siblings, four of whom are alive and healthy. His eldest sister died from a febrile cough at the age of five months. The second eldest sister died at the age of 18 years, from unknown causes, shortly after giving birth. At one year of age, P1 presented bronchitis requiring a short period of hospitalization. He subsequently had chicken-pox, with no complications. At the age of six years, he began to develop disseminated flat warts, mostly on the face, behind the ears, and on the upper and lower extremities. The skin lesions extended to the chest, the back and the perianal zone over the next few years of his life. During this period, the patient also developed lesions in the mouth, on the inner part of the lips and cheeks, and on the tongue. The skin lesions were found to be caused by EV-HPVs: HPV5, HPV15 and a third unclassified type by Southern Blot and PCR (data not shown). At the age of 13 years, the patient was hospitalized for severe pneumonia requiring intensive care and antibiotic treatment. He displayed no cardiac clinical phenotype and no electrocardiogram or echocardiographic abnormalities. He had Epstein Barr virus (EBV) infection, without severe symptoms, at the age of 14 years (1,500 copies/ml, determined by PCR). At the same age, the patient suffered from major tooth cavities and developed submental cervical adenopathy. The cervical lymph nodes were consequently removed. Histological analysis of one of the lymph nodes removed showed a fibrous thickening of the capsule associated with an increase in the abundance of plasmocytes and the presence of a few HHV8<sup>+</sup> cells and a few cells labeled with the Epstein-Barr-encoded RNA (EBER) probe. Since the age of 15, white patches testing positive for <italic>Candida albicans</italic> have regularly been observed in his mouth and treated with Fluconazole. At the age of 17, signs of autoimmunity were detected, with the presence of autoantibodies against proteinase 3 (cANCA) in the patient&#x2019;s serum (<xref ref-type="supplementary-material" rid="pone.0044010.s002">Table S1</xref>). All classical vaccines administered during childhood &#x2013; the live vaccines BCG (Monovax&#xAE;), measles, mumps and rubella and the surface antigen vaccines diphtheria, tetanus toxoid, poliovirus and HBV &#x2013; were carried out without complications, but PPD tests have remained negative. At 10 years old, the patient&#x2019;s growth curve presented a negative deviation from the norm. At the age of 17, stabilization at &#x2212;2SD (standard deviation) for weight and &#x2212;1SD for height was observed. The patient is now 19 years old and has been receiving immunoglobulin (Ig) replacement therapy since the age of 17 and antibiotic prophylaxis (Trimethoprim/Sulfamethoxazole) against infection since the age of 13.</p>
        <fig id="pone-0044010-g001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0044010.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Homozygous <italic>MST1</italic> nonsense mutation in one patient with EV-HPV, bacterial and fungal infections.</title>
            <p>(A) Pedigree of the family with EV-HPV, bacterial and fungal infections. Generations are designated by a Roman numeral (I, II). P1 is represented by a black symbol. The symbol *indicates the individuals genotyped with the Affymetrix Genome-wide SNP 6.0 array. The Familial segregation of the mutation R115X is shown on the pedigree. (B) Automated sequencing profile, showing the R115X <italic>MST1</italic> mutation in gDNA extracted from EBV-B cells from the patient and comparison with the sequence obtained from a healthy control. The C&#x2192;T mutation leads to the replacement at residue 115 of an Arg (R) residue by a STOP codon (X). (C) Schematic representation of the structure of the MST1 protein adapted from the work of Nehme <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>. R115X is situated in the kinase domain, close to the previously reported R117X mutation described by Nehme <italic>et al.,</italic> indicated by a black arrow. The second mutation (1103delT X369) described by Nehme <italic>et al.,</italic> 1103delT X369, and the mutation described by Abdollahpour <italic>et al.</italic> (W250X) <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref> are also indicated by black arrows.</p>
          </caption>
          <graphic xlink:href="pone.0044010.g001"/>
        </fig>
      </sec>
      <sec id="s2b">
        <title>Immunological Explorations</title>
        <p>We carried out a general immunophenotyping of the patient&#x2019;s peripheral blood cells at various ages, from nine to 19 years. The number of peripheral polymorphonuclear neutrophils gradually decreased over time, whereas monocyte counts were normal. The proportion of CD3<sup>+</sup> T cells was slightly lower than the normal range for age, from the age of 13 years onwards. This general T-cell lymphopenia was associated with more pronounced CD4<sup>+</sup> T-cell lymphopenia (<xref ref-type="table" rid="pone-0044010-t001">Table 1</xref>). CD8<sup>+</sup> T-cell counts and proportions were normal or higher than control values, depending on the experiment. The V&#x3B1;&#x3B2; repertoire of CD8<sup>+</sup> T cells had an abnormal distribution, with an excess of the V&#x3B2;14 subset (data not shown). Within the CD4<sup>+</sup> T-cell compartment, CD45RO<sup>+</sup> memory cells were present at a much higher level and CD45RA<sup>+</sup> naive T cells were much less frequent than normal (<xref ref-type="table" rid="pone-0044010-t001">Table 1</xref>). Within the naive subset, recent thymic T-cell emigrants (CD31<sup>+</sup>CD45RA<sup>+</sup>CD4<sup>+</sup>) were almost entirely absent in analyses of the patient&#x2019;s peripheral blood (<xref ref-type="table" rid="pone-0044010-t001">Table 1</xref>). We then studied the frequencies of the four functionally different types of CD8<sup>+</sup> T lymphocytes defined on the basis of CD45RA and CCR7 expression <xref ref-type="bibr" rid="pone.0044010-Romero1">[26]</xref>, when the patient reached 19 years of age. There were very few naive CD8<sup>+</sup> T cells (CCR7<sup>+</sup>CD45RA<sup>+</sup>CD8<sup>+</sup>), the percentage of these cells being well below the normal range. The percentage of central memory CD8<sup>+</sup> T cells (CCR7<sup>+</sup>CD45RA<sup>&#x2212;</sup>CD8<sup>+</sup>) was also lower than normal, whereas the proportion of cells belonging to the effector memory T<sub>EM</sub> (CCR7<sup>&#x2212;</sup>CD45RA<sup>&#x2212;</sup>CD8<sup>+</sup>) subset was normal. By contrast, the revertant memory T<sub>EMRA</sub> (CCR7<sup>&#x2212;</sup>CD45RA<sup>+</sup>CD8<sup>+</sup>) subset was more abundant than in controls (<xref ref-type="table" rid="pone-0044010-t001">Table 1</xref>). The frequencies of B and NK cells were normal (<xref ref-type="table" rid="pone-0044010-t001">Table 1</xref>).</p>
        <table-wrap id="pone-0044010-t001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0044010.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Immunophenotyping of the patient.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0044010-t001-1" xlink:href="pone.0044010.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td colspan="5" align="left" rowspan="1">Patient (normal range)<xref ref-type="table-fn" rid="nt101">A</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient&#x2019;s age</td>
                  <td align="left" rowspan="1" colspan="1">9 years</td>
                  <td align="left" rowspan="1" colspan="1">13 years</td>
                  <td align="left" rowspan="1" colspan="1">16 years</td>
                  <td align="left" rowspan="1" colspan="1">17 years</td>
                  <td align="left" rowspan="1" colspan="1">19 years</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Neutrophils (&#xD7;10<sup>9</sup>/l)</td>
                  <td align="left" rowspan="1" colspan="1">2.0 (1.5&#x2013;3.6)</td>
                  <td align="left" rowspan="1" colspan="1"><bold>1.0</bold> (1.5&#x2013;3.5)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1"><bold>0.8</bold> (1.5&#x2013;3.5)</td>
                  <td align="left" rowspan="1" colspan="1"><bold>1.0</bold> (1.5&#x2013;3.5)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Eosinophils (&#xD7;10<sup>9</sup>/l)</td>
                  <td align="left" rowspan="1" colspan="1">0.4 (&#x2264;0.8)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">0.1 (&#x2264;0.8)</td>
                  <td align="left" rowspan="1" colspan="1">0.1 (&#x2264;0.8)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Monocytes (&#xD7;10<sup>9</sup>/l)</td>
                  <td align="left" rowspan="1" colspan="1">0.6 (0.24&#x2013;0.75)<xref ref-type="table-fn" rid="nt102">B</xref></td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">0.5 (0.21&#x2013;0.73)<xref ref-type="table-fn" rid="nt102">B</xref></td>
                  <td align="left" rowspan="1" colspan="1">0.6 (0.21&#x2013;0.73)<xref ref-type="table-fn" rid="nt102">B</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Total lymphocytes (counts/&#xB5;l)</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">4,400 (1,900&#x2013;3,700)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>900</bold> (1,900&#x2013;3,700)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>600</bold> (1,400&#x2013;3,300)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>700</bold> (1,400&#x2013;3,300)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>900</bold> (1,400&#x2013;3,300)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>T cells</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD3<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1"><bold>48</bold> (60&#x2013;76)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">51 (56&#x2013;84)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">73 (56&#x2013;84)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">74 (56&#x2013;84)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>62</bold> (64&#x2013;85)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD3<sup>+</sup> counts <italic>(counts/&#xB5;l)</italic></td>
                  <td align="left" rowspan="1" colspan="1">2112 (1,200&#x2013;2,600)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>459</bold> (1,000&#x2013;2,200)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>438</bold> (1,000&#x2013;2,200)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>518</bold> (1,000&#x2013;2,200)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>558</bold> (807&#x2013;1844)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1"><bold>12</bold> (31&#x2013;47)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>18</bold> (31&#x2013;52)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>19</bold> (31&#x2013;52)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>27</bold> (31&#x2013;52)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">37 (34&#x2013;62)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> counts <italic>(counts/&#xB5;l)</italic></td>
                  <td align="left" rowspan="1" colspan="1"><bold>528</bold> (650&#x2013;1,500)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>162</bold> (530&#x2013;1,300)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>114</bold> (530&#x2013;1,300)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>189</bold> (530&#x2013;1,300)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>333</bold> (460&#x2013;1232)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">48 (18&#x2013;35)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">43 (18&#x2013;35)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">49 (18&#x2013;35)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">39 (18&#x2013;35)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">25 (14&#x2013;42)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup> counts <italic>(counts/&#xB5;l)</italic></td>
                  <td align="left" rowspan="1" colspan="1">2112 (370&#x2013;1,100)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">387 (330&#x2013;920)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>294</bold> (330&#x2013;920)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>273</bold> (330&#x2013;920)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">225 (187&#x2013;844)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD4<sup>+</sup>CD45RA<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">16 (33&#x2013;66)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">12 (33&#x2013;66)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">9 (33&#x2013;66)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>7</bold> (58&#x2013;70)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD4<sup>+</sup>CD45RO<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">84 (18&#x2013;38)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">88 (18&#x2013;38)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">91 (18&#x2013;38)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">93 (16&#x2013;34)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD4<sup>+</sup>CD31<sup>+</sup>CD45RA<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1"><bold>7</bold> (42&#x2013;74)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>7</bold> (42&#x2013;55)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>4</bold> (42&#x2013;55)<xref ref-type="table-fn" rid="nt103">C</xref></td>
                  <td align="left" rowspan="1" colspan="1"><bold>3</bold> (43&#x2013;55)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup>CCR7<sup>+</sup>CD45RA<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1"><bold>4</bold> (37&#x2013;50)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup>CCR7<sup>+</sup>CD45RA<sup>&#x2212;</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1"><bold>0.4</bold> (6&#x2013;16)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup>CCR7<sup>&#x2212;</sup>CD45RA<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">71 (8&#x2013;20)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD8<sup>+</sup>CCR7<sup>&#x2212;</sup>CD45RA<sup>&#x2212;</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">24 (24&#x2013;37)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">TcR&#x3B3;&#x3B4; (%) (2&#x2013;8<xref ref-type="table-fn" rid="nt101">A</xref>)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>B cells</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD19<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">9 (13&#x2013;27)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">14 (6&#x2013;23)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">9 (6&#x2013;23)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">11 (6&#x2013;23)<xref ref-type="table-fn" rid="nt104">D</xref></td>
                  <td align="left" rowspan="1" colspan="1">10 (6&#x2013;17)<xref ref-type="table-fn" rid="nt105">E</xref></td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD27<sup>+</sup>CD19<sup>+</sup> (%) (&gt;15<xref ref-type="table-fn" rid="nt101">A</xref>)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">27</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">30</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>NK cells</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD56<sup>+</sup>CD3<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">12</td>
                  <td align="left" rowspan="1" colspan="1">13</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD56<sup>+</sup>CD3<sup>&#x2212;</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">28 (6&#x2013;27)<xref ref-type="table-fn" rid="nt106">F</xref></td>
                  <td align="left" rowspan="1" colspan="1">14 (6&#x2013;27)<xref ref-type="table-fn" rid="nt106">F</xref></td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">CD16<sup>+</sup>CD56<sup>+</sup> (%)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">16 (3&#x2013;22)</td>
                  <td align="left" rowspan="1" colspan="1">22 (3&#x2013;22)</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <label>A</label>
              <p>Normal ranges were obtained from internal laboratory controls (N&#x200A;=&#x200A;10) unless specified otherwise.</p>
            </fn>
            <fn id="nt102">
              <label>B</label>
              <p>normal ranges from the work of Lugada <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Lugada1">[47]</xref>.</p>
            </fn>
            <fn id="nt103">
              <label>C</label>
              <p>normal ranges taken from the work of Nehme <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>.</p>
            </fn>
            <fn id="nt104">
              <label>D</label>
              <p>normal ranges taken from the work of Shearer <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Shearer1">[48]</xref>.</p>
            </fn>
            <fn id="nt105">
              <label>E</label>
              <p>normal ranges taken from the work of Bisset <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Bisset1">[49]</xref>.</p>
            </fn>
            <fn id="nt106">
              <label>F</label>
              <p>normal ranges taken from the work of Eidenscheck <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Eidenschenk1">[50]</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>We also investigated the proliferative response of T cells to various mitogens and antigens <italic>in vitro</italic> (<xref ref-type="table" rid="pone-0044010-t002">Table 2</xref>). The patient&#x2019;s T cells consistently responded poorly to mitogens (PHA, PMA + ionomycin) and the anti-CD3 antibody OKT3 and did not respond at all to recall antigens, despite normal immunization (tetanus anatoxin, PPD) or prior infection (<italic>C. albicans</italic>). The patient also had moderately high IgG levels, but very high levels of IgA and IgE (<xref ref-type="supplementary-material" rid="pone.0044010.s002">Table S1</xref>). Despite this hypergammaglobulinemia, the patient displayed a poor antibody response to several immunizations: no antibodies were produced against diphtheria, pneumococcus or <italic>Haemophilus influenzae</italic> and no allohemagglutinins against blood group antigens were detected. However, the patient did generate detectable amounts of antibodies against rubella and varicella zoster virus (VZV). The overall immunological features of the patient were consistent with a T-cell immunodeficiency.</p>
        <table-wrap id="pone-0044010-t002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0044010.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>T-cell proliferation in response to mitogens and antigens, as assessed by thymidine incorporation<xref ref-type="table-fn" rid="nt107">A</xref>.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0044010-t002-2" xlink:href="pone.0044010.t002"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Stimulus (normal range)<xref ref-type="table-fn" rid="nt108">B</xref></td>
                  <td colspan="5" align="left" rowspan="1">Patient (P1)</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Patient&#x2019;s age</td>
                  <td align="left" rowspan="1" colspan="1">9 years</td>
                  <td align="left" rowspan="1" colspan="1">13 years</td>
                  <td align="left" rowspan="1" colspan="1">14 years</td>
                  <td align="left" rowspan="1" colspan="1">16 years</td>
                  <td align="left" rowspan="1" colspan="1">18 years</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>3-day culture</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">PHA (&gt;50)</td>
                  <td align="left" rowspan="1" colspan="1">49</td>
                  <td align="left" rowspan="1" colspan="1">18</td>
                  <td align="left" rowspan="1" colspan="1">22</td>
                  <td align="left" rowspan="1" colspan="1">18</td>
                  <td align="left" rowspan="1" colspan="1">58.5</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">OKT3 (50 ng/ml ) (&gt;30)</td>
                  <td align="left" rowspan="1" colspan="1">10.6</td>
                  <td align="left" rowspan="1" colspan="1">17</td>
                  <td align="left" rowspan="1" colspan="1">24</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">PMA (10<sup>&#x2212;7</sup>M) + Ionomycin (10<sup>&#x2212;5</sup>M) (&gt;80)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">14</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">PMA (10<sup>&#x2212;8</sup>M) + Ionomycin (10<sup>&#x2212;6</sup>M) (&gt;80)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">0.10</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>6-day culture</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Tetanus toxoid (&gt;10)</td>
                  <td align="left" rowspan="1" colspan="1">0</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">0</td>
                  <td align="left" rowspan="1" colspan="1">0.2</td>
                  <td align="left" rowspan="1" colspan="1">1.4</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Tuberculin (&gt;10)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">6</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">0.4</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Candidin (&gt;10)</td>
                  <td align="left" rowspan="1" colspan="1">1.2</td>
                  <td align="left" rowspan="1" colspan="1">2.2</td>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1">0.1</td>
                  <td align="left" rowspan="1" colspan="1">1.2</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">HSV (&gt;10)</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">ND</td>
                  <td align="left" rowspan="1" colspan="1">0.1</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt107">
              <label>A</label>
              <p>3H-TdR incorporation in cpm/10<sup>3</sup>.</p>
            </fn>
            <fn id="nt108">
              <label>B</label>
              <p>normal ranges from internal laboratory controls.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s2c">
        <title>Genetics</title>
        <p>MHC class II deficiency was excluded, because HLA-DR expression on CD19<sup>+</sup> and CD14<sup>+</sup> cells was normal. Mutations of <italic>EVER1</italic>, <italic>EVER2</italic>, <italic>IL2RG</italic>, <italic>JAK3</italic>, <italic>CXCR4, RAG1, RAG2, ARTEMIS, TYK2</italic> were previously excluded by homozygosity mapping or direct sequencing. As the patient was born to consanguineous parents, we hypothesized that his immunodeficiency was inherited as an AR trait. We thus performed a genome-wide scan with the Affymetrix genome-wide SNP 6.0 array, followed by a multipoint genome-wide linkage (GWL) analysis with homozygosity mapping, using a complete penetrance model. We identified 17 regions on 11 chromosomes with a maximum LOD score of 1.33 (<xref ref-type="supplementary-material" rid="pone.0044010.s001">Figure S1</xref>). These regions covered a total of 81.7 Mb, containing 1,254 genes, including 707 protein-coding genes. We then carried out WES for the patient, covering 705 protein-coding genes in the linked regions (the <italic>TMEM185B</italic> gene encoding the transmembrane protein 185 B and <italic>MTRNR2L2</italic> encoding the MT-RNR2-like 2 protein were not covered) (data not shown) with a mean of 20.9 reads per gene. We identified 9,084 coding variations, after alignment and variant calling, 450 of which were not reported in the NCBI dbSNP 134 and the 1000 Genomes (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>) databases (<xref ref-type="table" rid="pone-0044010-t003">Table 3</xref>). Seven of these variations were in the linked regions, and six were homozygous. Among those six homozygous variants, only two were not present in our in-house database (composed of 615 exomes from patients with different clinical phenotypes): the I285V variant of the <italic>ERCC3</italic> gene (located in region 2q21) and the R115X variant of the <italic>STK4/MST1</italic> gene (located in region 20q11.2&#x2013;q13.2).</p>
        <table-wrap id="pone-0044010-t003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0044010.t003</object-id>
          <label>Table 3</label>
          <caption>
            <title>Whole-exome analysis of P1<xref ref-type="table-fn" rid="nt111">a</xref>.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0044010-t003-3" xlink:href="pone.0044010.t003"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Total coding</td>
                  <td align="left" rowspan="1" colspan="1">Coding in 1kgenomesand dbSNP134</td>
                  <td align="left" rowspan="1" colspan="1">Novel coding</td>
                  <td align="left" rowspan="1" colspan="1">Total essential splice</td>
                  <td align="left" rowspan="1" colspan="1">Novel essential splice</td>
                  <td align="left" rowspan="1" colspan="1">Total ncRNA</td>
                  <td align="left" rowspan="1" colspan="1">Novel ncRNA</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Whole Exome</td>
                  <td align="left" rowspan="1" colspan="1">9,084</td>
                  <td align="left" rowspan="1" colspan="1">8,634</td>
                  <td align="left" rowspan="1" colspan="1">450</td>
                  <td align="left" rowspan="1" colspan="1">340</td>
                  <td align="left" rowspan="1" colspan="1">8</td>
                  <td align="left" rowspan="1" colspan="1">840</td>
                  <td align="left" rowspan="1" colspan="1">39</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Linked regions</td>
                  <td align="left" rowspan="1" colspan="1">258</td>
                  <td align="left" rowspan="1" colspan="1">251</td>
                  <td align="left" rowspan="1" colspan="1">7</td>
                  <td align="left" rowspan="1" colspan="1">12</td>
                  <td align="left" rowspan="1" colspan="1">0</td>
                  <td align="left" rowspan="1" colspan="1">18</td>
                  <td align="left" rowspan="1" colspan="1">0</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt109">
              <p>Coding variants include missense, nonsense, frameshift, in-frame deletions and insertions and readthrough variants.</p>
            </fn>
            <fn id="nt110">
              <p>Essential splice variants include all variants found in the first two base pairs or the last two base pairs of introns.</p>
            </fn>
            <fn id="nt111">
              <label>a</label>
              <p>Both homozygous and heterozygous variations are included.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>The <italic>xeroderma pigmentosum type B (XPB)</italic> gene (<italic>ERCC3</italic>) encodes the excision repair cross-complementing rodent repair deficiency complementation group 3 protein, a DNA helicase in nucleotide excision repair that is also a subunit of a class II transcription factor. It is expressed widely, including in keratinocytes <xref ref-type="bibr" rid="pone.0044010-Eller1">[27]</xref>, <xref ref-type="bibr" rid="pone.0044010-Weeda1">[28]</xref>. Mutations of this gene have been found in patients suffering from xeroderma pigmentosum (XP) with or without Cockayne syndrome (CS) and in two patients suffering from trichothiodystrophy (TTD) <xref ref-type="bibr" rid="pone.0044010-Oh1">[29]</xref>. Of note, XP, CS and TTD are autosomal recessive inherited disorders <xref ref-type="bibr" rid="pone.0044010-Oh1">[29]</xref>. All patients with these conditions display sun sensitivity, often associated with a high susceptibility to skin cancers on areas of the body exposed to the sun and developmental or neurological features. Patients with CS also often have a short stature. In general, these patients neither present susceptibility to infections nor immunological defects <xref ref-type="bibr" rid="pone.0044010-Oh1">[29]</xref>. The I285V variant is located in the DNA recognition domain and is predicted to be &#x201C;tolerated&#x201D; by SIFT (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org">http://sift.jcvi.org</ext-link>) and &#x201C;benign&#x201D; by Polyphen2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>). However, this mutation is unlikely to account for the T-cell and EV-HPV infections of this patient, as these phenotypes have never before been reported in any of the nine patients with ERCC3 deficiency investigated <xref ref-type="bibr" rid="pone.0044010-Oh1">[29]</xref>, although it may have contributed to the growth retardation of P1. Moreover, none of the other typical phenotypic traits of ERCC3 deficiency were documented in the patient.</p>
        <p>MST1 (or STK4, serine/threonine kinase 4) deficiency was recently described by Nehme <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref> and Abdollahpour <italic>et al.</italic>
<xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref> in seven patients from three unrelated kindreds with a T-cell phenotype closely resembling that of P1. MST1 deficiency in humans has been shown to lead to CD4<sup>+</sup> T-cell lymphopenia, with naive CD4<sup>+</sup> and CD8<sup>+</sup> T-cell lymphopenia, high exhausted activated/memory CD8<sup>+</sup> T-cell counts and impairment of the response of T cells to stimulation with CD3 antibodies, various mitogens and recall antigens <xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>. It has also been associated with neutropenia <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref> and heart malformations in some patients <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref>. Furthermore, recurrent pulmonary infections, susceptibility to candidiasis and non regressing cutaneous warts caused by cutaneous alpha- and beta-HPVs have been reported in MST1-deficient patients <xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>, <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref>. However, the beta-HPV infected skin lesions observed in one patient were histologically different from the typical EV-HPV infected lesions observed in our patient and EV patients <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref>. Strictly speaking, none of the seven previously reported MST1-deficient patients displayed EV-HPV infections, even in a form associated with other infectious and tumoral signs (distinct from EV, which is defined by such lesions in otherwise healthy individuals). The homozygous R115X nonsense mutation of <italic>MST1</italic> was confirmed by Sanger sequencing (<xref ref-type="fig" rid="pone-0044010-g001">Figure 1B</xref>). It is located upstream from the previously reported mutations of this gene (<xref ref-type="fig" rid="pone-0044010-g001">Figure 1C</xref>), including the loss-of-expression mutation R117X. Methionine-driven translation re-initiation between codons 115 and 117 is not possible. The R115X allele segregated with the disease, with a complete penetrance, consistent with the results of GWL analysis. It therefore is highly likely that the mutation of the <italic>MST1</italic> gene found here is loss-of-expression and disease causing in this patient. All clinical manifestations in P1, except for the growth retardation, and all immunological anomalies, T cells anomalies in particular, can be explained by MST1 deficiency. The infectious diseases seen in some but not all MST1-deficient patients, including susceptibility to EV-HPV lesions, may reflect clinical exposure or the impact of modifier genes. The lack of cardiac anomaly in P1, like in 4 other MST1-deficient patients <xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>, may also reflect the impact of modifier genes or other genetic lesions in the 3 MST1-deficient patients with such anomalies <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref>.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>We report here the first patient with susceptibility to EV-HPV lesions due to MST1 deficiency. All patients with MST1 deficiency have a similar immunological phenotype, characterized by naive CD4<sup>+</sup> and CD8<sup>+</sup> T-cell lymphopenia in particular. Nehme <italic>et al.</italic> showed that MST1 deficiency was associated with an impairment of naive T-cell (CD4<sup>+</sup> and CD8<sup>+</sup>) survival and impairment of the homing of CD8<sup>+</sup> cells to secondary lymphoid organs, due to weak expression of the homing receptors CCR7 and CD62L <xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>. This homing defect is consistent with findings in the mouse model, in which MST1 deficiency leads to naive T-cell lymphopenia and an impaired egress of mature T lymphocytes from the thymus to secondary lymphoid organs, associated with an impaired chemotactic response to several chemokines, including the CCR7 ligands CCL19 and CCL21 <xref ref-type="bibr" rid="pone.0044010-Zhou1">[32]</xref>, <xref ref-type="bibr" rid="pone.0044010-Dong1">[33]</xref>. However, the infectious phenotype differs between patients. Previously reported patients displayed recurrent bacterial infections of the lower respiratory tract leading to bronchiectasis, recurrent HPV, HSV, VZV and <italic>Molluscum contagiosium</italic> infections of the skin, mucocutaneous candidiasis (CMC) and chronic EBV infections <xref ref-type="bibr" rid="pone.0044010-Nehme1">[30]</xref>, <xref ref-type="bibr" rid="pone.0044010-Abdollahpour1">[31]</xref>. All but one of these patients had had multiple infections by the age of four years. The remaining patient did not display any symptoms of the condition until the age of 10 years. By contrast, our patient presented recurrent pulmonary infections and recurrent oral candidiasis, but his cutaneous phenotype was limited to warts caused by beta-HPV infections, different from the cutaneous lesions observed in other patients with warts caused by other HPV infections <xref ref-type="bibr" rid="pone.0044010-Ramoz1">[4]</xref>. MST1 deficiency is therefore a genetic etiology of susceptibility to EV-HPVs. This experiment of nature suggests that T cells may be critical for protective immunity against cutaneous EV-HPVs, at least in some individuals, which is consistent with our recent discovery of RHOH deficiency in two siblings with EV-HPV lesions and other phenotypes <xref ref-type="bibr" rid="pone.0044010-Crequer1">[17]</xref>. Nevertheless, there is growing evidence in the mouse model that MST1, which was initially identified as a member of the Hippo tumor-suppressor pathway, negatively regulates cell proliferation and promotes cell differentiation by inactivation of the yes-associated protein, YAP, in various tissues, including the skin <xref ref-type="bibr" rid="pone.0044010-Avruch1">[34]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0044010-Schlegelmilch1">[36]</xref>. Inactivation of YAP alleviates its inhibition of the Notch transcriptional pathway, which is known to play an antiproliferative effect in keratinocytes and has recently been shown to be negatively regulated by the beta-HPV protein E6 <xref ref-type="bibr" rid="pone.0044010-Tan1">[37]</xref>. We therefore cannot rule out the possibility that MST1 plays a role similar to that of the EVER proteins in restricting viral replication in keratinocytes by keeping cell proliferation rates low. Further studies are required to decipher the cellular pathogenesis of susceptibility to EV-HPV infection, in patients with EV and mutations in <italic>EVER1</italic> or <italic>EVER2</italic>, and in patients with EV-HPV lesions in the context of other phenotypes and mutations in <italic>RHOH</italic> or <italic>MST1</italic>.</p>
    </sec>
    <sec sec-type="materials|methods" id="s4">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title>Ethics Statement</title>
        <p>This study was conducted in accordance with the Helsinki Declaration, with written informed consent obtained from each patient or the patient&#x2019;s family. Approval for this study was obtained from the French IRB (Comit&#xE9; de protection des personnes or CPP), INSERM and the Rockefeller IRB.</p>
      </sec>
      <sec id="s4b">
        <title>Genotyping and Linkage Analysis</title>
        <p>Genomic DNA was isolated from lymphoblastoid cell lines or whole-blood samples, by phenol/chloroform extraction. The two parents, the patient and his healthy sibling were genotyped with the Affymetrix Genome-wide SNP 6.0 array. Genotype calling was achieved with Affymetrix Power Tools (<ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.affx">http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.affx</ext-link>) for the four family members and for an additional sample of 200 individuals genotyped by the same platform, to improve the detection of genotype clusters. We discarded monomorphic SNPs, SNPs with a call rate lower than 100% and SNPs presenting Mendelian inconsistencies within the family. SNPs were further filtered with population-based filters. We then used about 87,300 high-quality SNP markers to carry out linkage analysis by homozygosity mapping, assuming autosomal recessive inheritance with complete penetrance. Parametric multipoint linkage analysis was carried out with the Merlin program <xref ref-type="bibr" rid="pone.0044010-Abecasis1">[38]</xref>. The Senegalese family founders and HapMap YRI trios were used to estimate allele frequencies and to define linkage clusters, with an <italic>r<sup>2</sup></italic> threshold of 0.4. We searched for homozygous deletions in patients, with PennCNV-joint <xref ref-type="bibr" rid="pone.0044010-Wang1">[39]</xref>, correcting for waviness. P1 presented no homozygous deletion within the linkage regions that encompassed known coding genes and was absent from the DGV database (<ext-link ext-link-type="uri" xlink:href="http://projects.tcag.ca/variation/">http://projects.tcag.ca/variation/</ext-link>) (data not shown).</p>
      </sec>
      <sec id="s4c">
        <title>Sequencing</title>
        <p>Polymerase chain reaction (PCR) was carried out with <italic>Taq</italic> polymerase (Invitrogen, Carlsbad, California, USA) and the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, California, USA). Primer sequences are available upon request. The PCR products were sequenced with the BigDye Terminator Cycle sequencing kit (Applied Biosystems). Sequencing products were purified by centrifugation through Sephadex G-50 Superfine resin and sequences were analyzed with a 3730 DNA Analyzer (Applied Biosystems).</p>
      </sec>
      <sec id="s4d">
        <title>Whole-exome Sequencing</title>
        <p>Exome capture was performed with the Agilent SureSelect Human All Exon 50 Mb kit (Agilent Technologies). Paired-end sequencing was performed on an Illumina HiSeq 2000 (Illumina) generating 100-base reads. We aligned the sequences with the hg19 reference build of the human genome, using the BWA aligner <xref ref-type="bibr" rid="pone.0044010-Li1">[40]</xref>. Downstream processing and variant calling were carried out with the Genome Analysis Toolkit (GATK) <xref ref-type="bibr" rid="pone.0044010-McKenna1">[41]</xref>, Samtools <xref ref-type="bibr" rid="pone.0044010-Li2">[42]</xref> and Picard (<ext-link ext-link-type="uri" xlink:href="http://picard.sourceforge.net">http://picard.sourceforge.net</ext-link>). Substitution and InDel calls were made with GATK UnifiedGenotyper. All calls with a read coverage &lt;2&#xD7; and a phred-scaled SNP quality of 20 were filtered out. Variants were annotated with GATK GenomicAnnotator.</p>
      </sec>
      <sec id="s4e">
        <title>Antibodies</title>
        <p>The anti-CD3 mAb OKT3 (IgG2a) has been described elsewhere <xref ref-type="bibr" rid="pone.0044010-Tunnacliffe1">[43]</xref>. Immunologic analysis of the T-, B-, and NK cell compartments of whole-blood samples was performed by flow cytometry with monoclonal antibodies against CD3, CD4, CD8, CD19, CD16, CD45RA, CD45RO and CD31 (Becton Dickinson), as described elsewhere <xref ref-type="bibr" rid="pone.0044010-AndreSchmutz1">[44]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0044010-deVillartay1">[46]</xref>.</p>
      </sec>
      <sec id="s4f">
        <title>Thymidine Incorporation Assay</title>
        <p>PBMCs were incubated for three days alone or with PHA (2.5 &#xB5;g/ml), or the monoclonal soluble anti-CD3 antibody OKT3 (10, 25, 50 ng/ml), or PMA (10<sup>&#x2212;7</sup> or 10<sup>&#x2212;8</sup> M) plus ionomycin (10<sup>&#x2212;5</sup> or 10<sup>&#x2212;6</sup> M), or for six days with tetanus toxoid (0.2&#x2013;0.4 &#xB5;g/ml), HSV, tuberculin (5 &#xB5;g/ml) or candidin (50 &#xB5;g/ml). Cultures were pulsed with tritiated thymidine for the last 18 hours of the incubation period. The radioactivity incorporated was determined with a Matrix 96 beta counter (Canberra Packard, Frankfurt/Main, Germany). Cell proliferation was assessed by determining the cpm for [<sup>3</sup>H] thymidine incorporation, as previously described <xref ref-type="bibr" rid="pone.0044010-deSaintBasile1">[45]</xref>, <xref ref-type="bibr" rid="pone.0044010-deVillartay1">[46]</xref>.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="s5">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0044010.s001">
        <label>Figure S1</label>
        <caption>
          <p><bold>Analysis of multipoint linkage between the patient&#x2019;s disease and chromosomes 1, 2, 3, 4, 5, 8, 11, 12, 14, 16, 20, with a full penetrance model.</bold> Only chromosomes including regions with a maximal LOD score are shown. LOD scores (Y axis) are plotted against chromosomal position (in cM). The locations of <italic>ERCC3</italic> and <italic>MST1</italic> are indicated by black arrows.</p>
          <p>(TIF)</p>
        </caption>
        <media xlink:href="pone.0044010.s001.tif" mimetype="image" mime-subtype="tiff">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0044010.s002">
        <label>Table S1</label>
        <caption>
          <p>Humoral immunity of the patient&#x2019;s peripheral blood before Ig substitution.</p>
          <p>(DOCX)</p>
        </caption>
        <media xlink:href="pone.0044010.s002.docx" mimetype="application" mime-subtype="msword">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank the members of both branches of the Saint Giles Laboratory of Human Genetics of Infectious Diseases. We also would like to thank Corinne Jacques, Chantal Harre, Stephanie N&#x2019;Daga, Nathalie Lambert and Aminata Diabate for excellent technical assistance and Yelena Nemirovskaya and Eric Anderson for logistic assistance. We thank Minji Byun, Melina Herman and Alexandre Bolze for critical reading. We warmly thank the patient and his family for their participation.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0044010-Orth1">
        <label>1</label>
        <mixed-citation publication-type="journal"><name><surname>Orth</surname><given-names>G</given-names></name> (<year>2006</year>) <article-title>Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses</article-title>. <source>Semin Immunol</source><volume>18</volume>: <fpage>362</fpage>&#x2013;<lpage>374</lpage><pub-id pub-id-type="pmid">17011789</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Orth2">
        <label>2</label>
        <mixed-citation publication-type="journal"><name><surname>Orth</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis</article-title>. <source>Curr Top Microbiol Immunol</source><volume>321</volume>: <fpage>59</fpage>&#x2013;<lpage>83</lpage><pub-id pub-id-type="pmid">18727487</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Cockayne1">
        <label>3</label>
        <mixed-citation publication-type="other">Cockayne E (1933) Inherited abnormalities of the skin and its appendages. Oxford University Press, London.</mixed-citation>
      </ref>
      <ref id="pone.0044010-Ramoz1">
        <label>4</label>
        <mixed-citation publication-type="journal"><name><surname>Ramoz</surname><given-names>N</given-names></name>, <name><surname>Rueda</surname><given-names>LA</given-names></name>, <name><surname>Bouadjar</surname><given-names>B</given-names></name>, <name><surname>Montoya</surname><given-names>LS</given-names></name>, <name><surname>Orth</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis</article-title>. <source>Nat Genet</source><volume>32</volume>: <fpage>579</fpage>&#x2013;<lpage>581</lpage><pub-id pub-id-type="pmid">12426567</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Casanova1">
        <label>5</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2005</year>) <article-title>Inborn errors of immunity to infection: the rule rather than the exception</article-title>. <source>J Exp Med</source><volume>202</volume>: <fpage>197</fpage>&#x2013;<lpage>201</lpage><pub-id pub-id-type="pmid">16027233</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Casanova2">
        <label>6</label>
        <mixed-citation publication-type="journal"><name><surname>Casanova</surname><given-names>JL</given-names></name>, <name><surname>Abel</surname><given-names>L</given-names></name> (<year>2007</year>) <article-title>Primary immunodeficiencies: a field in its infancy</article-title>. <source>Science</source><volume>317</volume>: <fpage>617</fpage>&#x2013;<lpage>619</lpage><pub-id pub-id-type="pmid">17673650</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Alcais1">
        <label>7</label>
        <mixed-citation publication-type="journal"><name><surname>Alcais</surname><given-names>A</given-names></name>, <name><surname>Abel</surname><given-names>L</given-names></name>, <name><surname>Casanova</surname><given-names>JL</given-names></name> (<year>2009</year>) <article-title>Human genetics of infectious diseases: between proof of principle and paradigm</article-title>. <source>J Clin Invest</source><volume>119</volume>: <fpage>2506</fpage>&#x2013;<lpage>2514</lpage><pub-id pub-id-type="pmid">19729848</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Alcais2">
        <label>8</label>
        <mixed-citation publication-type="journal"><name><surname>Alcais</surname><given-names>A</given-names></name>, <name><surname>Quintana-Murci</surname><given-names>L</given-names></name>, <name><surname>Thaler</surname><given-names>DS</given-names></name>, <name><surname>Schurr</surname><given-names>E</given-names></name>, <name><surname>Abel</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity</article-title>? <source>Ann N Y Acad Sci</source><volume>1214</volume>: <fpage>18</fpage>&#x2013;<lpage>33</lpage><pub-id pub-id-type="pmid">21091717</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Lazarczyk1">
        <label>9</label>
        <mixed-citation publication-type="journal"><name><surname>Lazarczyk</surname><given-names>M</given-names></name>, <name><surname>Pons</surname><given-names>C</given-names></name>, <name><surname>Mendoza</surname><given-names>JA</given-names></name>, <name><surname>Cassonnet</surname><given-names>P</given-names></name>, <name><surname>Jacob</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses</article-title>. <source>J Exp Med</source><volume>205</volume>: <fpage>35</fpage>&#x2013;<lpage>42</lpage><pub-id pub-id-type="pmid">18158319</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Aochi1">
        <label>10</label>
        <mixed-citation publication-type="journal"><name><surname>Aochi</surname><given-names>S</given-names></name>, <name><surname>Nakanishi</surname><given-names>G</given-names></name>, <name><surname>Suzuki</surname><given-names>N</given-names></name>, <name><surname>Setsu</surname><given-names>N</given-names></name>, <name><surname>Suzuki</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>A novel homozygous mutation of the <italic>EVER1/TMC6</italic> gene in a Japanese patient with epidermodysplasia verruciformis</article-title>. <source>Br J Dermatol</source><volume>157</volume>: <fpage>1265</fpage>&#x2013;<lpage>1266</lpage><pub-id pub-id-type="pmid">17916203</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Berthelot1">
        <label>11</label>
        <mixed-citation publication-type="journal"><name><surname>Berthelot</surname><given-names>C</given-names></name>, <name><surname>Dickerson</surname><given-names>MC</given-names></name>, <name><surname>Rady</surname><given-names>P</given-names></name>, <name><surname>He</surname><given-names>Q</given-names></name>, <name><surname>Niroomand</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Treatment of a patient with epidermodysplasia verruciformis carrying a novel <italic>EVER2</italic> mutation with imiquimod</article-title>. <source>J Am Acad Dermatol</source><volume>56</volume>: <fpage>882</fpage>&#x2013;<lpage>886</lpage><pub-id pub-id-type="pmid">17368633</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Gober1">
        <label>12</label>
        <mixed-citation publication-type="journal"><name><surname>Gober</surname><given-names>MD</given-names></name>, <name><surname>Rady</surname><given-names>PL</given-names></name>, <name><surname>He</surname><given-names>Q</given-names></name>, <name><surname>Tucker</surname><given-names>SB</given-names></name>, <name><surname>Tyring</surname><given-names>SK</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Novel homozygous frameshift mutation of <italic>EVER1</italic> gene in an epidermodysplasia verruciformis patient</article-title>. <source>J Invest Dermatol</source><volume>127</volume>: <fpage>817</fpage>&#x2013;<lpage>820</lpage><pub-id pub-id-type="pmid">17139267</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Zuo1">
        <label>13</label>
        <mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>YG</given-names></name>, <name><surname>Ma</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Qiao</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>B</given-names></name> (<year>2006</year>) <article-title>Identification of a novel mutation and a genetic polymorphism of <italic>EVER1</italic> gene in two families with epidermodysplasia verruciformis</article-title>. <source>J Dermatol Sci</source><volume>44</volume>: <fpage>153</fpage>&#x2013;<lpage>159</lpage><pub-id pub-id-type="pmid">17008061</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Sun1">
        <label>14</label>
        <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>XK</given-names></name>, <name><surname>Chen</surname><given-names>JF</given-names></name>, <name><surname>Xu</surname><given-names>AE</given-names></name> (<year>2005</year>) <article-title>A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis</article-title>. <source>Clin Exp Dermatol</source><volume>30</volume>: <fpage>573</fpage>&#x2013;<lpage>574</lpage><pub-id pub-id-type="pmid">16045695</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Tate1">
        <label>15</label>
        <mixed-citation publication-type="journal"><name><surname>Tate</surname><given-names>G</given-names></name>, <name><surname>Suzuki</surname><given-names>T</given-names></name>, <name><surname>Kishimoto</surname><given-names>K</given-names></name>, <name><surname>Mitsuya</surname><given-names>T</given-names></name> (<year>2004</year>) <article-title>Novel mutations of <italic>EVER1/TMC6</italic> gene in a Japanese patient with epidermodysplasia verruciformis</article-title>. <source>J Hum Genet</source><volume>49</volume>: <fpage>223</fpage>&#x2013;<lpage>225</lpage><pub-id pub-id-type="pmid">15042430</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Rady1">
        <label>16</label>
        <mixed-citation publication-type="journal"><name><surname>Rady</surname><given-names>PL</given-names></name>, <name><surname>De Oliveira</surname><given-names>WR</given-names></name>, <name><surname>He</surname><given-names>Q</given-names></name>, <name><surname>Festa</surname><given-names>C</given-names></name>, <name><surname>Rivitti</surname><given-names>EA</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family</article-title>. <source>Br J Dermatol</source><volume>157</volume>: <fpage>831</fpage>&#x2013;<lpage>833</lpage><pub-id pub-id-type="pmid">17711520</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Crequer1">
        <label>17</label>
        <mixed-citation publication-type="other">Crequer A, Troeger A, Patin E, Ma CS, Picard C, <etal>et al</etal> (2012) Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. Journal of Clinical Investigation in Press.</mixed-citation>
      </ref>
      <ref id="pone.0044010-Rogers1">
        <label>18</label>
        <mixed-citation publication-type="journal"><name><surname>Rogers</surname><given-names>HD</given-names></name>, <name><surname>Macgregor</surname><given-names>JL</given-names></name>, <name><surname>Nord</surname><given-names>KM</given-names></name>, <name><surname>Tyring</surname><given-names>S</given-names></name>, <name><surname>Rady</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Acquired epidermodysplasia verruciformis</article-title>. <source>J Am Acad Dermatol</source><volume>60</volume>: <fpage>315</fpage>&#x2013;<lpage>320</lpage><pub-id pub-id-type="pmid">19150275</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Daly1">
        <label>19</label>
        <mixed-citation publication-type="other">Daly ML, Hay RJ (2012) Epidermodysplasia verruciformis and human immunodeficiency virus infection: a distinct entity? Curr Opin Infect Dis.</mixed-citation>
      </ref>
      <ref id="pone.0044010-Lutzner1">
        <label>20</label>
        <mixed-citation publication-type="journal"><name><surname>Lutzner</surname><given-names>MA</given-names></name> (<year>1985</year>) <article-title>Papillomavirus lesions in immunodepression and immunosuppression</article-title>. <source>Clin Dermatol</source><volume>3</volume>: <fpage>165</fpage>&#x2013;<lpage>169</lpage><pub-id pub-id-type="pmid">2850855</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Gross1">
        <label>21</label>
        <mixed-citation publication-type="journal"><name><surname>Gross</surname><given-names>G</given-names></name>, <name><surname>Ellinger</surname><given-names>K</given-names></name>, <name><surname>Roussaki</surname><given-names>A</given-names></name>, <name><surname>Fuchs</surname><given-names>PG</given-names></name>, <name><surname>Peter</surname><given-names>HH</given-names></name>, <etal>et al</etal> (<year>1988</year>) <article-title>Epidermodysplasia verruciformis in a patient with Hodgkin&#x2019;s disease: characterization of a new papillomavirus type and interferon treatment</article-title>. <source>J Invest Dermatol</source><volume>91</volume>: <fpage>43</fpage>&#x2013;<lpage>48</lpage><pub-id pub-id-type="pmid">2838553</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Laffort1">
        <label>22</label>
        <mixed-citation publication-type="journal"><name><surname>Laffort</surname><given-names>C</given-names></name>, <name><surname>Le Deist</surname><given-names>F</given-names></name>, <name><surname>Favre</surname><given-names>M</given-names></name>, <name><surname>Caillat-Zucman</surname><given-names>S</given-names></name>, <name><surname>Radford-Weiss</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency</article-title>. <source>Lancet</source><volume>363</volume>: <fpage>2051</fpage>&#x2013;<lpage>2054</lpage><pub-id pub-id-type="pmid">15207958</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Byun1">
        <label>23</label>
        <mixed-citation publication-type="journal"><name><surname>Byun</surname><given-names>M</given-names></name>, <name><surname>Abhyankar</surname><given-names>A</given-names></name>, <name><surname>Lelarge</surname><given-names>V</given-names></name>, <name><surname>Plancoulaine</surname><given-names>S</given-names></name>, <name><surname>Palanduz</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma</article-title>. <source>J Exp Med</source><volume>207</volume>: <fpage>2307</fpage>&#x2013;<lpage>2312</lpage><pub-id pub-id-type="pmid">20876309</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Bolze1">
        <label>24</label>
        <mixed-citation publication-type="journal"><name><surname>Bolze</surname><given-names>A</given-names></name>, <name><surname>Byun</surname><given-names>M</given-names></name>, <name><surname>McDonald</surname><given-names>D</given-names></name>, <name><surname>Morgan</surname><given-names>NV</given-names></name>, <name><surname>Abhyankar</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Whole-exome-sequencing-based discovery of human FADD deficiency</article-title>. <source>Am J Hum Genet</source><volume>87</volume>: <fpage>873</fpage>&#x2013;<lpage>881</lpage><pub-id pub-id-type="pmid">21109225</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Liu1">
        <label>25</label>
        <mixed-citation publication-type="journal"><article-title>Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis</article-title>. <source>J Exp Med</source><volume>208</volume>: <fpage>1635</fpage>&#x2013;<lpage>1648</lpage><pub-id pub-id-type="pmid">21727188</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Romero1">
        <label>26</label>
        <mixed-citation publication-type="journal"><name><surname>Romero</surname><given-names>P</given-names></name>, <name><surname>Zippelius</surname><given-names>A</given-names></name>, <name><surname>Kurth</surname><given-names>I</given-names></name>, <name><surname>Pittet</surname><given-names>MJ</given-names></name>, <name><surname>Touvrey</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Four functionally distinct populations of human effector-memory CD8+ T lymphocytes</article-title>. <source>J Immunol</source><volume>178</volume>: <fpage>4112</fpage>&#x2013;<lpage>4119</lpage><pub-id pub-id-type="pmid">17371966</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Eller1">
        <label>27</label>
        <mixed-citation publication-type="journal"><name><surname>Eller</surname><given-names>MS</given-names></name>, <name><surname>Maeda</surname><given-names>T</given-names></name>, <name><surname>Magnoni</surname><given-names>C</given-names></name>, <name><surname>Atwal</surname><given-names>D</given-names></name>, <name><surname>Gilchrest</surname><given-names>BA</given-names></name> (<year>1997</year>) <article-title>Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>94</volume>: <fpage>12627</fpage>&#x2013;<lpage>12632</lpage><pub-id pub-id-type="pmid">9356500</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Weeda1">
        <label>28</label>
        <mixed-citation publication-type="journal"><name><surname>Weeda</surname><given-names>G</given-names></name>, <name><surname>Ma</surname><given-names>LB</given-names></name>, <name><surname>van Ham</surname><given-names>RC</given-names></name>, <name><surname>van der Eb</surname><given-names>AJ</given-names></name>, <name><surname>Hoeijmakers</surname><given-names>JH</given-names></name> (<year>1991</year>) <article-title>Structure and expression of the human XPBC/ERCC-3 gene involved in DNA repair disorders xeroderma pigmentosum and Cockayne&#x2019;s syndrome</article-title>. <source>Nucleic Acids Res</source><volume>19</volume>: <fpage>6301</fpage>&#x2013;<lpage>6308</lpage><pub-id pub-id-type="pmid">1956789</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Oh1">
        <label>29</label>
        <mixed-citation publication-type="journal"><name><surname>Oh</surname><given-names>KS</given-names></name>, <name><surname>Khan</surname><given-names>SG</given-names></name>, <name><surname>Jaspers</surname><given-names>NG</given-names></name>, <name><surname>Raams</surname><given-names>A</given-names></name>, <name><surname>Ueda</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome</article-title>. <source>Hum Mutat</source><volume>27</volume>: <fpage>1092</fpage>&#x2013;<lpage>1103</lpage><pub-id pub-id-type="pmid">16947863</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Nehme1">
        <label>30</label>
        <mixed-citation publication-type="other">Nehme NT, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, <etal>et al</etal> (2011) MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T cells survival. Blood 10.1182/blood-2011-09-378364.</mixed-citation>
      </ref>
      <ref id="pone.0044010-Abdollahpour1">
        <label>31</label>
        <mixed-citation publication-type="other">Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, <etal>et al</etal> (2012) The phenotype of human STK4 deficiency. Blood 10.1182/blood-2011-09-378158.</mixed-citation>
      </ref>
      <ref id="pone.0044010-Zhou1">
        <label>32</label>
        <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>D</given-names></name>, <name><surname>Medoff</surname><given-names>BD</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>XF</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naive T cells</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>105</volume>: <fpage>20321</fpage>&#x2013;<lpage>20326</lpage><pub-id pub-id-type="pmid">19073936</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Dong1">
        <label>33</label>
        <mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>Y</given-names></name>, <name><surname>Du</surname><given-names>X</given-names></name>, <name><surname>Ye</surname><given-names>J</given-names></name>, <name><surname>Han</surname><given-names>M</given-names></name>, <name><surname>Xu</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A cell-intrinsic role for Mst1 in regulating thymocyte egress</article-title>. <source>J Immunol</source><volume>183</volume>: <fpage>3865</fpage>&#x2013;<lpage>3872</lpage><pub-id pub-id-type="pmid">19692642</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Avruch1">
        <label>34</label>
        <mixed-citation publication-type="journal"><name><surname>Avruch</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>D</given-names></name>, <name><surname>Fitamant</surname><given-names>J</given-names></name>, <name><surname>Bardeesy</surname><given-names>N</given-names></name> (<year>2011</year>) <article-title>Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development</article-title>. <source>Br J Cancer</source><volume>104</volume>: <fpage>24</fpage>&#x2013;<lpage>32</lpage><pub-id pub-id-type="pmid">21102585</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Lee1">
        <label>35</label>
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>TS</given-names></name>, <name><surname>Yang</surname><given-names>TH</given-names></name>, <name><surname>Koo</surname><given-names>BK</given-names></name>, <name><surname>Oh</surname><given-names>SP</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>A crucial role of WW45 in developing epithelial tissues in the mouse</article-title>. <source>EMBO J</source><volume>27</volume>: <fpage>1231</fpage>&#x2013;<lpage>1242</lpage><pub-id pub-id-type="pmid">18369314</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Schlegelmilch1">
        <label>36</label>
        <mixed-citation publication-type="journal"><name><surname>Schlegelmilch</surname><given-names>K</given-names></name>, <name><surname>Mohseni</surname><given-names>M</given-names></name>, <name><surname>Kirak</surname><given-names>O</given-names></name>, <name><surname>Pruszak</surname><given-names>J</given-names></name>, <name><surname>Rodriguez</surname><given-names>JR</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Yap1 acts downstream of alpha-catenin to control epidermal proliferation</article-title>. <source>Cell</source><volume>144</volume>: <fpage>782</fpage>&#x2013;<lpage>795</lpage><pub-id pub-id-type="pmid">21376238</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Tan1">
        <label>37</label>
        <mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>MJ</given-names></name>, <name><surname>White</surname><given-names>EA</given-names></name>, <name><surname>Sowa</surname><given-names>ME</given-names></name>, <name><surname>Harper</surname><given-names>JW</given-names></name>, <name><surname>Aster</surname><given-names>JC</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Cutaneous beta-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>109</volume>: <fpage>E1473</fpage>&#x2013;<lpage>1480</lpage><pub-id pub-id-type="pmid">22547818</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Abecasis1">
        <label>38</label>
        <mixed-citation publication-type="journal"><name><surname>Abecasis</surname><given-names>GR</given-names></name>, <name><surname>Cherny</surname><given-names>SS</given-names></name>, <name><surname>Cookson</surname><given-names>WO</given-names></name>, <name><surname>Cardon</surname><given-names>LR</given-names></name> (<year>2002</year>) <article-title>Merlin&#x2013;rapid analysis of dense genetic maps using sparse gene flow trees</article-title>. <source>Nat Genet</source><volume>30</volume>: <fpage>97</fpage>&#x2013;<lpage>101</lpage><pub-id pub-id-type="pmid">11731797</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Wang1">
        <label>39</label>
        <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Tadesse</surname><given-names>MG</given-names></name>, <name><surname>Glessner</surname><given-names>J</given-names></name>, <name><surname>Grant</surname><given-names>SF</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Modeling genetic inheritance of copy number variations</article-title>. <source>Nucleic Acids Res</source><volume>36</volume>: <fpage>e138</fpage><pub-id pub-id-type="pmid">18832372</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Li1">
        <label>40</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source><volume>25</volume>: <fpage>1754</fpage>&#x2013;<lpage>1760</lpage><pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-McKenna1">
        <label>41</label>
        <mixed-citation publication-type="journal"><name><surname>McKenna</surname><given-names>A</given-names></name>, <name><surname>Hanna</surname><given-names>M</given-names></name>, <name><surname>Banks</surname><given-names>E</given-names></name>, <name><surname>Sivachenko</surname><given-names>A</given-names></name>, <name><surname>Cibulskis</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source>Genome Res</source><volume>20</volume>: <fpage>1297</fpage>&#x2013;<lpage>1303</lpage><pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Li2">
        <label>42</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Handsaker</surname><given-names>B</given-names></name>, <name><surname>Wysoker</surname><given-names>A</given-names></name>, <name><surname>Fennell</surname><given-names>T</given-names></name>, <name><surname>Ruan</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The Sequence Alignment/Map format and SAMtools</article-title>. <source>Bioinformatics</source><volume>25</volume>: <fpage>2078</fpage>&#x2013;<lpage>2079</lpage><pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Tunnacliffe1">
        <label>43</label>
        <mixed-citation publication-type="journal"><name><surname>Tunnacliffe</surname><given-names>A</given-names></name>, <name><surname>Olsson</surname><given-names>C</given-names></name>, <name><surname>de la Hera</surname><given-names>A</given-names></name> (<year>1989</year>) <article-title>The majority of human CD3 epitopes are conferred by the epsilon chain</article-title>. <source>Int Immunol</source><volume>1</volume>: <fpage>546</fpage>&#x2013;<lpage>550</lpage><pub-id pub-id-type="pmid">2484963</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-AndreSchmutz1">
        <label>44</label>
        <mixed-citation publication-type="journal"><name><surname>Andre-Schmutz</surname><given-names>I</given-names></name>, <name><surname>Le Deist</surname><given-names>F</given-names></name>, <name><surname>Hacein-Bey-Abina</surname><given-names>S</given-names></name>, <name><surname>Vitetta</surname><given-names>E</given-names></name>, <name><surname>Schindler</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study</article-title>. <source>Lancet</source><volume>360</volume>: <fpage>130</fpage>&#x2013;<lpage>137</lpage><pub-id pub-id-type="pmid">12126823</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-deSaintBasile1">
        <label>45</label>
        <mixed-citation publication-type="journal"><name><surname>de Saint Basile</surname><given-names>G</given-names></name>, <name><surname>Geissmann</surname><given-names>F</given-names></name>, <name><surname>Flori</surname><given-names>E</given-names></name>, <name><surname>Uring-Lambert</surname><given-names>B</given-names></name>, <name><surname>Soudais</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3</article-title>. <source>J Clin Invest</source><volume>114</volume>: <fpage>1512</fpage>&#x2013;<lpage>1517</lpage><pub-id pub-id-type="pmid">15546002</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-deVillartay1">
        <label>46</label>
        <mixed-citation publication-type="journal"><name><surname>de Villartay</surname><given-names>JP</given-names></name>, <name><surname>Lim</surname><given-names>A</given-names></name>, <name><surname>Al-Mousa</surname><given-names>H</given-names></name>, <name><surname>Dupont</surname><given-names>S</given-names></name>, <name><surname>Dechanet-Merville</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection</article-title>. <source>J Clin Invest</source><volume>115</volume>: <fpage>3291</fpage>&#x2013;<lpage>3299</lpage><pub-id pub-id-type="pmid">16276422</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Lugada1">
        <label>47</label>
        <mixed-citation publication-type="journal"><name><surname>Lugada</surname><given-names>ES</given-names></name>, <name><surname>Mermin</surname><given-names>J</given-names></name>, <name><surname>Kaharuza</surname><given-names>F</given-names></name>, <name><surname>Ulvestad</surname><given-names>E</given-names></name>, <name><surname>Were</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Population-based hematologic and immunologic reference values for a healthy Ugandan population</article-title>. <source>Clin Diagn Lab Immunol</source><volume>11</volume>: <fpage>29</fpage>&#x2013;<lpage>34</lpage><pub-id pub-id-type="pmid">14715541</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Shearer1">
        <label>48</label>
        <mixed-citation publication-type="journal"><name><surname>Shearer</surname><given-names>WT</given-names></name>, <name><surname>Rosenblatt</surname><given-names>HM</given-names></name>, <name><surname>Gelman</surname><given-names>RS</given-names></name>, <name><surname>Oyomopito</surname><given-names>R</given-names></name>, <name><surname>Plaeger</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study</article-title>. <source>J Allergy Clin Immunol</source><volume>112</volume>: <fpage>973</fpage>&#x2013;<lpage>980</lpage><pub-id pub-id-type="pmid">14610491</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Bisset1">
        <label>49</label>
        <mixed-citation publication-type="journal"><name><surname>Bisset</surname><given-names>LR</given-names></name>, <name><surname>Lung</surname><given-names>TL</given-names></name>, <name><surname>Kaelin</surname><given-names>M</given-names></name>, <name><surname>Ludwig</surname><given-names>E</given-names></name>, <name><surname>Dubs</surname><given-names>RW</given-names></name> (<year>2004</year>) <article-title>Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland</article-title>. <source>Eur J Haematol</source><volume>72</volume>: <fpage>203</fpage>&#x2013;<lpage>212</lpage><pub-id pub-id-type="pmid">14962239</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0044010-Eidenschenk1">
        <label>50</label>
        <mixed-citation publication-type="journal"><name><surname>Eidenschenk</surname><given-names>C</given-names></name>, <name><surname>Jouanguy</surname><given-names>E</given-names></name>, <name><surname>Alcais</surname><given-names>A</given-names></name>, <name><surname>Mention</surname><given-names>JJ</given-names></name>, <name><surname>Pasquier</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes</article-title>. <source>J Immunol</source><volume>177</volume>: <fpage>8835</fpage>&#x2013;<lpage>8843</lpage><pub-id pub-id-type="pmid">17142786</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
